This trial is evaluating whether JNJ-64251330 will improve 2 primary outcomes and 15 secondary outcomes in patients with Adenomatous Polyposis Coli. Measurement will happen over the course of Baseline and Week 24.
This trial requires 40 total participants across 1 different treatment group
This trial involves a single treatment. JNJ-64251330 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Jnj-6402336 inhibits GSK3beta phosphorylation at residues Serine 9 (GKS9), Thracein (TKS5), and Serine 21 (GSK21), thereby inhibiting the phosphorylation of multiple targets including CREB and Cdk2. Jnj-6402336 has been shown to be effective against breast cancer and melanoma cells. It has also been demonstrated to have antitumor activity against T cell acute lymphoblastic leukemia, multiple myeloma, and prostate cancer in rodent models. Recent findings shows that Jnj-6402336 exhibits significant antitumor activity in vivo even at low doses." - Anonymous Online Contributor
"In infants with APC mutations, intestinal polyps are common but asymptomatic. These polyps may be easily removed during colonoscopy, allowing normal growth of the infant's bowel. The significance of these polyps remains unclear. The delay in diagnosis of APC mutation should be considered when counseling families on the risks and benefits of surveillance colonoscopies." - Anonymous Online Contributor
"Adenomatous polyposis coli patients receive many different types of medications. Most of them are used to treat either intestinal or external conditions. There are many things on the web that suggest what medicines might help adenomatous polyposis coli patients. However, there is little evidence to show exactly how well each type of medication helps adenomatous polyposis coli patients. In fact, there are many studies showing that some medications are worse than others. For example, some medications can cause problems with liver function (especially if taken over longer periods of time) and can lead to death. Therefore, it's important that you review all of the information before deciding which medications would be most helpful for you." - Anonymous Online Contributor
"The current study demonstrated that Jnj-64251330 was more effective than a placebo in reducing polyp size and enhancing adenoma regression rate. This is the first report of long-term efficacy of this compound against colorectal neoplasia." - Anonymous Online Contributor
"The present study shows that Jnj-64251330 is active against carcinogenesis and tumourigenesis induced by DMBA and lacks toxic effects in vivo. Although more studies are needed to evaluate the safety and efficacy of Jnj-64251330 in humans, this drug may provide a new therapeutic approach for the prevention and treatment of cancer." - Anonymous Online Contributor
"This article examines the role of clinical trials in APC gene therapy, a promising new therapeutic approach for patients with APC mutant tumors. Clinical trials are needed to evaluate APC gene therapy before it can be used more widely." - Anonymous Online Contributor
"Jnj-64251330 exhibits potent antiproliferative activity against colorectal cancer cells through inhibition of Akt phosphorylation. Results from a recent clinical trial may have important implications in the development of novel anticancer therapeutics." - Anonymous Online Contributor
"Adenomatous polyposis coli is caused by mutations in APC which results in increased risk of colorectal cancer development. Patients with APC mutated tumors also have an increased risk of developing vulvar carcinoma." - Anonymous Online Contributor
"The risk of APC gene mutation increases with advancing age, smoking, and female sex. It may be prudent for family members to consider genetic testing when they develop colorectal lesions suggestive of APC mutation. In addition, careful surveillance will be necessary for any person identified with APC mutation." - Anonymous Online Contributor
"There have not been any new discoveries for treating APC mutations. However, new studies are being done to determine if certain genetic testing will help patients get their APC gene corrected so they may be able to pass on genes that keep them healthy." - Anonymous Online Contributor